18 Results for "

PSMA-positive cells

" in MedChemExpress (MCE) Product Catalog:
Products (18)

18 Results for "PSMA-positive cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-148152A
Purity:  98.15%
Target:  

PSMA

Research Areas:  

Cancer

PSMA I&S TFA is a PSMA-targeted imaging agent. PSMA I&S TFA undergoes PSMA-mediated internalization into PSMA-expressing cells, with uptake into PSMA-positive tissues competitively inhibited by a potent PSMA inhibitor. PSMA I&S TFA can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-P9992
CAS No.: 2414550-93-7
Synonyms: BAY-2315497; PSMA-TTC

Target:  

PSMA Apoptosis

Research Areas:  

Cancer

Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-117756
CAS No.: 1423758-00-2
Purity:  99.10%
Synonyms: DCFPYL
Target:  

PSMA

Research Areas:  

Cancer

Piflufolastat (DCFPYL) can be used for the preparation of piflufolastat F 18 (DCFPyL F-18). Piflufolastat F-18 (DCFPyL F-18) is an 18F-labeled imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) targeting prostate-specific membrane antigen (PSMA). Piflufolastat can be used for imaging of prostate cancer .
loading...
    loading...
Cat. No.: HY-159500
CAS No.: 2206660-94-6
Synonyms: OTL-0078; OTL78
Target:  

PSMA

Research Areas:  

Cancer

Zopocianine (OTL-0078; OTL78) is a near-infrared optical probe targeting PSMA. Zopocianine binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine is applicable to research related to prostate cancer .
loading...
    loading...
Cat. No.: HY-114256
CAS No.: 1610413-96-1
Target:  

PSMA

Research Areas:  

Cancer

EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .
loading...
    loading...
Cat. No.: HY-129615
CAS No.: 949575-20-6
Research Areas:  

Cancer

MIP-1072 is a competitive prostate-specific membrane antigen (PSMA) inhibitor with a Ki value of 4.6 nM. MIP-1072 specifically binds to PSMA and is internalized into PSMA-expressing prostate cancer cells. MIP-1072 accumulates in PSMA-expressing prostate cancer xenografts. MIP-1072 specifically blocks the uptake of 68Ga-NOTA-GUL by PSMA-positive prostate cancer xenografts. When radiolabeled with 123I, MIP-1072 functions as a SPECT/CT molecular imaging agent. MIP-1072 can be used in prostate cancer-related research .
loading...
    loading...
Cat. No.: HY-169336
CAS No.: 3024354-59-1
Target:  

PARP PSMA

Research Areas:  

Cancer

CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))
loading...
    loading...
Cat. No.: HY-159500A
CAS No.: 2206660-95-7
Synonyms: OTL-0078 sodium; OTL78 sodium
Target:  

PSMA

Research Areas:  

Cancer

Zopocianine sodium (OTL-0078 sodium; OTL78 sodium) is a near-infrared optical probe targeting PSMA. Zopocianine sodium binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine sodium selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine sodium helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine sodium is applicable to research related to prostate cancer .
loading...
    loading...
Cat. No.: HY-181830
Target:  

PD-1/PD-L1 PSMA LYTACs

Research Areas:  

Cancer

Atz-L5 is a PD-L1 PTAC (PSMA-targeted chimera) degrader (DC50: 18 pM in PC3-PIP cells; 2 pM in LNCaP cells) and LYTAC. Atz-L5 promotes lysosomal degradation of PD-L1 in PSMA-positive prostate cancer cells. Atz-L5 is applicable to the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-181829
Target:  

EGFR PSMA LYTACs

Research Areas:  

Cancer

Ctx-L3 is a selective EGFR PTAC (PSMA-targeted chimera) degrader (DC50: 4.3 pM in LNCaP cells) and LYTAC. Ctx-L3 recruits prostate-specific membrane antigen (PSMA) and mediates lysosomal degradation of EGFR in PSMA-positive prostate cancer cells. Ctx-L3 exhibits degrading activity against EGFR in prostate cancer cells. Ctx-L3 is applicable to related research on prostate cancer .
loading...
    loading...
Cat. No.: HY-182240
Target:  

PSMA

Research Areas:  

Cancer

Cy5-ZW2-617 is a PSMA ligand with a IC50 of 4.39 nM. Cy5-ZW2-617 specifically binds to PSMA and is thereby internalized by PSMA-positive cells. Cy5-ZW2-617 shows uptake in PSMA-positive tumor cells and tumor xenografts in mice. Cy5-ZW2-617 can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-178248
CAS No.: 2576410-20-1
Target:  

PSMA

Research Areas:  

Cancer

PSMA ligand 2 is a prostate specific membrane antigen (PSMA) ligand with a glutamate-urea-lysine (GUL) moiety. PSMA ligand 2 can be efficiently labeled with radioactive nuclides such as 68Ga and 177Lu and specifically binds to PSMA-positive tumor cells. PSMA ligand 2 can be used for imaging of PSMA-expressing tumors or cells via PET or SPECT imaging. PSMA ligand 2 can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-P11893
Target:  

PSMA

Research Areas:  

Cancer

PSMA-HK9 is a ligand targeting prostate-specific membrane antigen (PSMA) that binds to PSMA with high affinity, with a Kd value of 4.76 nM. PSMA-HK9 can be labeled with the diagnostic radionuclide 68Ga for imaging applications, and this labeled conjugate exhibits high tumor uptake and low normal tissue uptake in vivo. PSMA-HK9 can be labeled with the radionuclide 177Lu for targeted radionuclide studies, and this labeled conjugate possesses efficient cellular endocytosis and tumor inhibitory activity. PSMA-HK9 can be used in studies related to prostate cancer .
loading...
    loading...
Cat. No.: HY-181853
Research Areas:  

Cancer

NOTA-SP₂A-PSMAL is a ligand targeting prostate-specific membrane antigen (PSMA), which competitively binds to PSMA with high binding affinity and an IC50 value of 0.26 nM. 18F-labeled NOTA-SP2A-PSMAL can be used as a PET tracer for positron emission tomography imaging of prostate cancer. NOTA-SP2A-PSMAL can be used for the synthesis and research of radionuclide conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-W1129940
CAS No.: 2417821-30-6
Research Areas:  

Cancer

p-SCN-Macropa is a bifunctional macrocyclic chelator featuring macrocyclic polyamine skeletons and thiocyanate (-SCN) reactive moieties. p-SCN-Macropa can conjugate with monoclonal antibodies including Nimotuzumab (HY-P9968), Rituximab (HY-P9913) and Trastuzumab (HY-P9907)-PEG6-DM1 for 225Ac radiolabeling to construct radioimmunoconjugates. p-SCN-Macropa is applicable for the research of colorectal cancer, HER2-positive breast cancer, TROP-2-positive cancers, and PSMA-positive cancers .
loading...
    loading...
Cat. No.: HY-P992094
CAS No.: 151763-64-3

Target:  

PSMA

Research Areas:  

Cancer

Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-185729
Synonyms: ADCT-401
Research Areas:  

Cancer

MEDI3726 (ADCT-401) is a prostate-specific membrane antigen (PSMA)-targeting antibody-drug conjugate (ADC), composed of LP Tesirine (HY-128952) and antibody J591 (HY-P991359). MEDI3726 binds PSMA’s extracellular domain, triggers endocytosis, undergoes lysosomal degradation to release a pyrrolobenzodiazepine warhead. MEDI3726 induces DNA crosslinking, DNA damage, cell death, cytotoxicity, and inhibits tumor growth in mouse xenograft models. MEDI3726 undergoes in vivo catabolism primarily via heavy-light chain dissociation, with minimal warhead deconjugation. MEDI3726 can be used for the research of metastatic castration-resistant prostate cancer and prostate cancers .
loading...
    loading...
Cat. No.: HY-P11591
CAS No.: 3110124-60-9
Synonyms: PSMA-DOTA-PEI2
Research Areas:  

Cancer

PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer .
loading...
    loading...
  • 1